What Does Ebola Look Like on a Person’s Body?

Ebola virus disease produces a distinctive progression of visible changes on the body, beginning with a dark-red, bumpy rash that has been described as giving the skin a “ghost-like” appearance and, in severe cases, advancing to bleeding from multiple sites. The rash typically appears between days four and six of illness, but it is only one layer of a disease that reshapes the skin, eyes, and mucous membranes over the course of an infection and sometimes long after recovery. What makes Ebola’s outward signs especially tricky is that the earliest visible clues can be subtle and easily mistaken for other tropical fevers, while the most dramatic signs tend to arrive late, when the disease has already progressed far.

The First Days Look Like the Flu

Before anything shows up on the skin, Ebola announces itself with symptoms that could belong to dozens of other infections. A sudden high fever, severe headache, muscle and joint pain, and deep fatigue hit abruptly. Gastrointestinal symptoms follow quickly: in the 1976 Sudan outbreak, diarrhea was reported in about 81% of cases, vomiting in roughly 59%, and chest pain in around 83%.¹ Pain and dryness in the throat were also common. At this stage, nothing on the skin distinguishes Ebola from malaria, typhoid, or a bad case of influenza, which is one reason early outbreaks have been so difficult to contain.

The Rash That Appears Around Day Four to Six

The first skin sign specific to Ebola is a rash that typically emerges between the fourth and sixth day of illness. It is a maculopapular eruption, meaning the skin develops both flat discolored patches and small raised bumps. The color tends toward dark red, and the surface of the rash often has a fine scaling quality that early clinical observers described as giving the patient a “ghost-like” look.² The rash does not itch, which helps set it apart from many other tropical skin reactions.

The eruption usually starts on the upper arms and upper thighs and then spreads inward toward the trunk in a centripetal pattern.² Early on, the lesions appear in scattered patches, particularly on the extremities and torso. As the disease progresses, those patches coalesce and can become confluent, covering broader swaths of skin.³ The overall appearance at this point can resemble measles-like (morbilliform) rashes, which makes clinical context critical: a maculopapular rash in a person with recent travel to an Ebola-endemic region, combined with high fever and gastrointestinal distress, is a strong signal.

Skin Tone Makes a Real Difference in Detection

One clinically important and often overlooked detail is that the Ebola rash is far more easily recognized on lighter skin. During the Sudan outbreak, about 52% of infected individuals were noted to have a morbilliform rash or skin peeling in later stages, but field clinicians acknowledged that detecting the rash on darker skin tones was significantly harder.³ In some non-Caucasian patients, desquamation, the peeling of skin that occurs later in the disease, was the first visible indication that skin was involved at all.

This is not a minor footnote. The majority of Ebola outbreaks have occurred in sub-Saharan Africa, where the population predominantly has darker skin. If the rash is routinely missed in these patients, clinicians lose a diagnostic clue at a stage when isolation and supportive care could still make a difference. Research into better dermatological descriptions across skin tones for filovirus infections remains a recognized gap in the literature.

Hemorrhagic Signs in Severe Cases

The word “hemorrhagic” in Ebola hemorrhagic fever refers to bleeding that can occur from multiple sites on and inside the body. In the Sudan outbreak, hemorrhagic manifestations were reported in roughly 71% of cases, appearing in about half of those who survived and in nearly all fatal cases.¹ On the body’s surface, this can look like spontaneous bruising, bleeding from the gums, nosebleeds, oozing from needle puncture sites (a particularly alarming sign in clinical settings), and blood in vomit or stool. Petechiae, tiny pinpoint hemorrhages under the skin, can appear scattered across the chest and limbs.

Despite its dramatic reputation, overt external bleeding is not always the most prominent feature. Many Ebola patients die from internal organ failure, dehydration, and shock rather than from visible hemorrhage. The bleeding that does appear externally, though, is often what makes Ebola visually terrifying: blood-tinged tears, blood seeping from the gums, and dark bruising across limbs all contribute to the disease’s fearsome image. Not every patient reaches this stage. The likelihood and severity of bleeding depend on the viral strain, the patient’s immune response, and the quality of supportive care available.

What Happens to the Eyes

The eyes are affected in ways that are both visible to others and distressing for the patient. Subconjunctival hemorrhage, where blood pools beneath the thin membrane covering the white of the eye, gives the eyes a strikingly red or bloodshot appearance. Excessive tearing has also been reported during the acute phase.⁴ For someone looking at a patient, red eyes combined with facial swelling and the ghost-like rash create a distinctive and unsettling picture.

Eye problems do not necessarily resolve when the acute infection clears. In a study of 96 Ebola survivors in Monrovia, Liberia, 21 developed uveitis (inflammation inside the eye) linked to their Ebola infection, and 3 developed optic neuropathy, which can impair vision significantly.⁵ Eye inflammation in survivors can persist for months and, in some cases, leads to lasting vision loss. Ebola RNA has been detected in aqueous humor (the fluid inside the eye) as long as 101 days after the onset of illness, suggesting the virus can linger in immune-privileged sites long after the bloodstream has cleared it.⁶

Why the Skin and Blood Vessels Break Down

The visible signs on the skin and the bleeding both trace back to what Ebola does to the cells lining blood vessels. The virus’s surface glycoprotein activates the endothelial cells that form the inner wall of blood vessels and causes those cells to lose their barrier function, the ability to keep fluids and blood cells inside the vessels where they belong.⁷ When that barrier breaks down, fluid leaks into surrounding tissues (causing swelling), blood components escape (causing bruising, petechiae, and overt bleeding), and the skin’s normal structure is disrupted from underneath.

The rash, the hemorrhaging, and the eventual skin peeling are all downstream consequences of this vascular damage. It is not that the virus attacks the skin directly at first. Instead, the blood vessels feeding the skin become leaky and inflamed, and the skin reflects the chaos happening beneath it. The gastrointestinal bleeding and internal organ damage follow the same principle in their respective vascular beds.

Virus on the Skin’s Surface During Late Infection

A detail that underscores both the danger and the visible impact of Ebola is that infectious virus actually reaches the outer surface of the skin during late-stage disease. Research using human skin tissue models showed that Ebola infects multiple cell types in the skin, including immune cells, cells lining small blood vessels, and connective tissue cells in the deeper layers, along with the keratinocytes that make up the outermost barrier. Infectious virus was detected on the outer skin surface within three days in those models, indicating the virus propagates and traffics outward through the tissue layers.⁸

This helps explain why contact with a patient’s skin or bodily fluids during late illness is so dangerous for caregivers. Ebola RNA has been detected in sweat up to 44 days after illness onset.⁶ The visible state of the skin during this phase, often a combination of rash, peeling, bruising, and sometimes oozing, is not just a symptom. It is an active route through which the virus exits the body.

What Ebola Looks Like After the Patient Survives

Recovery from Ebola does not mean the skin returns to normal overnight. Many survivors experience a period of widespread skin peeling, particularly on the hands, feet, and limbs. Generalized dry skin and itching, along with desquamation affecting the palms and soles, have been consistently reported in survivors across multiple outbreaks.⁹ The peeling can be dramatic, with large sheets of skin coming away, and it may persist for weeks after the fever and bleeding have resolved.

Hair loss is another visible sequela. Among the Liberian survivors studied, hair loss was one of the systemic symptoms noted alongside joint pain and fatigue.⁵ Combined with continued eye redness or clouding from uveitis, skin peeling, and visible weight loss from the prolonged illness, survivors can look markedly different from their pre-illness selves for months. In communities where Ebola has struck, these lasting physical changes can carry social stigma, making survivors identifiable and sometimes subject to discrimination even after they are no longer contagious.

How Long the Virus Lingers in the Body

Even after someone has recovered and their blood tests negative for Ebola, the virus can persist in certain body compartments for remarkably long periods. Ebola RNA has been found in semen up to 18 months after illness onset, in breast milk up to 16 months (in preliminary data), and in cerebrospinal fluid up to 9 months.⁶ While these are not skin findings the way a rash is, they matter for what the disease “looks like” in a broader sense: a survivor may appear outwardly healthy while still harboring detectable viral genetic material in body fluids. This has practical implications for partners, for women who are breastfeeding, and for healthcare workers following up with survivors.

The persistence of virus in the eyes, as mentioned earlier with aqueous humor detection out to 101 days, can also produce visible signs that linger. Uveitis in survivors can cause a red, painful eye that is noticeable to others. In the worst cases, cataracts or vision changes leave lasting physical evidence of the disease.

Skin Findings as a Diagnostic Tool

An underappreciated aspect of Ebola’s skin involvement is its potential diagnostic value. The clinical progression of the disease moves through three overlapping phases: a general systemic phase (fever, aches), a gastrointestinal phase (vomiting, diarrhea), and a mucocutaneous phase (rash, bleeding from mucous membranes, skin changes). While the rash itself is nonspecific and cannot reliably distinguish Ebola from other hemorrhagic or febrile illnesses on appearance alone, laboratory examination of skin tissue can confirm the diagnosis. Immunohistochemical staining of skin biopsy or post-mortem specimens can identify Ebola virus antigens in the tissue, providing confirmation even when blood testing is not available or practical.¹⁰

In outbreak settings with limited laboratory infrastructure, the combination of clinical signs, including the characteristic rash pattern and timing, remains one of the frontline tools for case identification. A patient presenting with sudden high fever, severe gastrointestinal symptoms, a non-itchy dark rash appearing on the limbs around day five, and any sign of bleeding represents a classic clinical picture that should trigger immediate isolation and confirmatory testing. The rash alone does not make the diagnosis, but its presence in the right clinical context speeds it up considerably.

Differences Between Ebola Strains and Outbreaks

Not every Ebola outbreak produces the same visible picture. The species of Ebola virus matters. Ebola virus (formerly Zaire ebolavirus), the strain responsible for the largest outbreaks including the 2013–2016 West African epidemic, carries the highest fatality rate and tends to produce the most severe hemorrhagic signs. Sudan ebolavirus, responsible for the 1976 Sudan outbreak, also produces hemorrhagic manifestations but with somewhat lower fatality rates historically. Bundibugyo and Taï Forest strains have caused smaller outbreaks with varying clinical profiles. Reston ebolavirus, which has been found in nonhuman primates, has infected humans without causing symptomatic disease, so it produces no visible signs at all.

The quality of supportive care also shapes what the disease looks like on the body. In outbreaks where aggressive fluid replacement, electrolyte management, and monitoring are available, patients may never develop the full hemorrhagic picture because the underlying dehydration and organ failure are addressed before they spiral. In resource-limited settings, the progression to visible bleeding and severe skin breakdown happens more often simply because the disease runs its course without intervention. The same virus, in different healthcare contexts, can produce visually very different clinical courses.

1
PubMed Central. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team
2
PubMed Central. Skin manifestation and diagnosis of febrile diseases by COVID-19 and other ribonucleic acid viruses – Section: EBOLA VIRUS
3
Dermatologic Clinics. Filovirus hemorrhagic fevers: Marburg and Ebola – Section: Clinical features
4
PubMed Central. What we know about ocular manifestations of Ebola – Section: Abstract
5
PubMed Central. Ophthalmic Manifestations and Causes of Vision Impairment in Ebola Virus Disease Survivors in Monrovia, Liberia – Section: Results
6
PubMed Central. Ebola Virus Shedding and Transmission: Review of Current Evidence – Section: Abstract
7
PubMed Central. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function
8
PubMed Central. Multiple cell types support productive infection and dynamic translocation of infectious Ebola virus to the surface of human skin – Section: Abstract
9
The Lancet Infectious Diseases. Sequelae of Ebola virus disease – Section: Skin disorders
10
PubMed Central. Cutaneous manifestations of filovirus infections